Prenetics Global (NASDAQ:PRE – Get Free Report) and Cytek Biosciences (NASDAQ:CTKB – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, profitability, risk, analyst recommendations, dividends, earnings and institutional ownership.
Insider & Institutional Ownership
25.0% of Prenetics Global shares are owned by institutional investors. Comparatively, 69.5% of Cytek Biosciences shares are owned by institutional investors. 7.8% of Prenetics Global shares are owned by company insiders. Comparatively, 9.6% of Cytek Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Valuation and Earnings
This table compares Prenetics Global and Cytek Biosciences”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Prenetics Global | $25.56 million | 2.60 | -$62.72 million | ($3.99) | -1.36 |
| Cytek Biosciences | $201.21 million | 3.35 | -$12.15 million | ($0.08) | -65.38 |
Analyst Recommendations
This is a breakdown of recent ratings and recommmendations for Prenetics Global and Cytek Biosciences, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Prenetics Global | 0 | 0 | 1 | 0 | 3.00 |
| Cytek Biosciences | 1 | 0 | 1 | 0 | 2.00 |
Prenetics Global presently has a consensus target price of $9.00, indicating a potential upside of 65.59%. Cytek Biosciences has a consensus target price of $6.50, indicating a potential upside of 24.28%. Given Prenetics Global’s stronger consensus rating and higher possible upside, research analysts clearly believe Prenetics Global is more favorable than Cytek Biosciences.
Risk and Volatility
Prenetics Global has a beta of -0.31, suggesting that its share price is 131% less volatile than the S&P 500. Comparatively, Cytek Biosciences has a beta of 1.4, suggesting that its share price is 40% more volatile than the S&P 500.
Profitability
This table compares Prenetics Global and Cytek Biosciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Prenetics Global | -191.73% | -16.45% | -13.34% |
| Cytek Biosciences | -5.05% | -2.58% | -2.05% |
Summary
Cytek Biosciences beats Prenetics Global on 10 of the 13 factors compared between the two stocks.
About Prenetics Global
Prenetics Global Limited, a genomics-driven health sciences company, engages in revolutionizing prevention, early detection, and treatment. It offers CircleDNA, a prevention arm that uses whole exome sequencing to offer comprehensive consumer DNA test. The company also, through its joint venture, Insighta, engages in pioneering multi-cancer early detection technologies. In addition, the company, through its equity interests in ACT Genomics Holdings Company Limited, is involved in genomic profiling of solid tumors through ACTOnco. Prenetics Global Limited was founded in 2007 and is based in Quarry Bay, Hong Kong.
About Cytek Biosciences
Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems. The company also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, an automated loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in European, Latin American, and the Middle Eastern countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.
Receive News & Ratings for Prenetics Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prenetics Global and related companies with MarketBeat.com's FREE daily email newsletter.
